Sirnaomics in the News

Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year

31

2022-08

Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases

30

2022-08

After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology

23

2022-02

Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public

16

2021-07

RNA Silencing Finds Its Therapeutic Voice

01

2020-03

Hunt for New Coronavirus Treatments Includes Gene-Silencing And Monoclonal Antibodies

19

2020-02

Coronavirus: AbbVie and Sirnaomics Drug Candidates Explored

27

2020-01

Sirnaomics to Develop RNAi-based Therapeutics for 2019-nCoV Infections

27

2020-01

Innovent and Sirnaomics to Combine Sintilimab and RNAi in Cancer

08

2020-01

Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

08

2020-01

Sirnaomics cleared to start first trial of RNAi lead in cancer

17

2019-08

Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline

03

2019-06

Sirnaomics adds $22M to series C, backing therapies for cancer and fibrotic disease

01

2019-05

Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human

cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice.

01

2019-05

Eyeing RNAi potential in cancer and fibrosis, trans-Pacific biotech Sirnaomics lines up $47M Series C

29

2019-04

Sirnaomics closes second portion of $47M Series C round for RNA-interference drugs

29

2019-04

Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer

and Fibrotic Diseases

25

2019-04

FDA gives green light to study of cholangiocarcinoma drug

17

2018-08

Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer

16

2018-08

Sirnaomics raises $25 million in Series C1 round for RNAi drug

08

2018-06

China’s Yuexiu New Industrial Investment leads $18m round for Sirnaomics

07

2018-06

Sirnaomics Closed US$25M Series C1 Financing

06

2018-06

ChinaBio® Partnering Forum 2017: Sirnaomics prioritizes China in parallel with US RNAi development

15

2017-07